LP
RARE icon

Longaeva Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Longaeva Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.78M Buy
+228,107
New +$5.14M 0.18% 113

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Longaeva Partners's RARE Position: Q1 2026 in Review

Longaeva Partners opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 228,107 shares worth $4.78M. The stake represents 0.18% of the portfolio and ranks #113 among its holdings.

295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Longaeva Partners held 228,107 shares of Ultragenyx Pharmaceutical worth $4.78M as of Q1 2026.
  • Ultragenyx Pharmaceutical was a new Longaeva Partners position in Q1 2026.
  • Ultragenyx Pharmaceutical made up 0.18% of Longaeva Partners's portfolio in Q1 2026, its #113 holding.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.